|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...2021222324252627282930...6768» |
- ||| lenalidomide / Generic mfg.
Enrollment change, Trial primary completion date: Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide (clinicaltrials.gov) - Jul 16, 2015
P2, N=82, Recruiting, Sponsor: Mayo Clinic
N=41 --> 82 | Trial primary completion date: Dec 2015 --> May 2016
- ATryn (antithrombin) / LFB Biotechnologies, Knight Therap
Enrollment change, Trial termination, Surgery: Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery (clinicaltrials.gov) - Jul 15, 2015
P4, N=42, Terminated, Sponsor: Mayo Clinic
N=41 --> 82 | Trial primary completion date: Dec 2015 --> May 2016 N=60 --> 42 | Suspended --> Terminated; Too many barriers to enroll participants.
- ||||||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial completion: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (clinicaltrials.gov) - Jul 15, 2015
P3, N=62, Completed, Sponsor: Amgen
N=60 --> 42 | Suspended --> Terminated; Too many barriers to enroll participants. Active, not recruiting --> Completed
- afuresertib (LAE002) / Laekna Therap
Trial primary completion date, Combination therapy: Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma (clinicaltrials.gov) - Jul 15, 2015
P1, N=90, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Trial primary completion date: May 2015 --> Aug 2015
- | melphalan / Generic mfg., pomalidomide / Generic mfg.
Clinical: Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 15, 2015
P2, N=40, Completed, Sponsor: Yale University
Trial primary completion date: May 2015 --> Aug 2015 Active, not recruiting --> Completed
- Darzalex (daratumumab) / J&J
New P1 trial, Combination therapy: A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 14, 2015
P1, N=6, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
- Trial completion: HERO: To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives (clinicaltrials.gov) - Jul 10, 2015
P=N/A, N=200, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Xyntha (moroctocog alfa) / Pfizer
Trial primary completion date: Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients (clinicaltrials.gov) - Jul 10, 2015
P4, N=50, Recruiting, Sponsor: Pfizer
Enrolling by invitation --> Completed Trial primary completion date: Aug 2019 --> May 2016
- | Rituxan (rituximab) / Roche
Enrollment change: Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma (clinicaltrials.gov) - Jul 10, 2015
P2, N=21, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Aug 2019 --> May 2016 N=29 --> 21
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Enrollment change, Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant (clinicaltrials.gov) - Jul 10, 2015
P2, N=6, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=29 --> 21 Active, not recruiting --> Completed | N=88 --> 6 | Trial primary completion date: Sep 2014 --> Dec 2011
- ||||| Xyntha (moroctocog alfa) / Pfizer
New P4 trial: PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A (clinicaltrials.gov) - Jul 9, 2015
P4, N=90, Recruiting, Sponsor: Pfizer
- Trial primary completion date, Metastases: Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss (clinicaltrials.gov) - Jul 9, 2015
P1/2, N=63, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | N=88 --> 6 | Trial primary completion date: Sep 2014 --> Dec 2011 Trial primary completion date: Nov 2004 --> Jul 2004
- MRX34 / Synlogic
Enrollment change: A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection (clinicaltrials.gov) - Jul 9, 2015
P1, N=120, Recruiting, Sponsor: Mirna Therapeutics, Inc.
Trial primary completion date: Nov 2004 --> Jul 2004 N=48 --> 120
- decitabine / Generic mfg.
Enrollment change, Trial initiation date, Trial primary completion date: A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia (clinicaltrials.gov) - Jul 9, 2015
P2, N=20, Recruiting, Sponsor: Shandong University
N=48 --> 120 N=60 --> 20 | Initiation date: Jun 2013 --> Jun 2014 | Trial primary completion date: Dec 2015 --> Dec 2016
- bortezomib / Generic mfg., dexamethasone injection / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment closed, Enrollment change: A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jul 9, 2015
P2, N=19, Active, not recruiting, Sponsor: Shanghai Changzheng Hospital
N=60 --> 20 | Initiation date: Jun 2013 --> Jun 2014 | Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting | N=72 --> 19
- | baclofen / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer (clinicaltrials.gov) - Jul 9, 2015
P3, N=211, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting | N=72 --> 19 Active, not recruiting --> Completed | N=148 --> 211 | Trial primary completion date: Jan 2010 --> Apr 2009
- Alhemo (concizumab) / Novo Nordisk
New P1 trial: Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (clinicaltrials.gov) - Jul 8, 2015
P1, N=45, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Beleodaq (belinostat) / Aurobindo, Assertio
Trial completion, Metastases: Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma (clinicaltrials.gov) - Jul 7, 2015
P2, N=25, Completed, Sponsor: Onxeo
Active, not recruiting --> Completed | N=148 --> 211 | Trial primary completion date: Jan 2010 --> Apr 2009 No longer recruiting --> Completed
- Enrollment closed, Enrollment change: Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Jul 6, 2015
P2/3, N=16, Active, not recruiting, Sponsor: Laboratoire français de Fractionnement et de Biotechnologies
No longer recruiting --> Completed Recruiting --> Active, not recruiting | N=12 --> 16
- bortezomib / Generic mfg., dexamethasone / Generic mfg., bendamustine / Generic mfg.
Trial primary completion date: Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy (clinicaltrials.gov) - Jul 6, 2015
P2, N=42, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting | N=12 --> 16 Trial primary completion date: Jun 2015 --> Jun 2016
- balixafortide (POL 6326) / Spexis
Enrollment change, Trial primary completion date, Metastases: Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jul 6, 2015
P1/2, N=80, Recruiting, Sponsor: Polyphor Ltd.
Trial primary completion date: Jun 2015 --> Jun 2016 N=60 --> 80 | Trial primary completion date: Dec 2014 --> Dec 2016
- lenalidomide / Generic mfg.
Enrollment closed, IO biomarker: FMG-MM02: First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02 (clinicaltrials.gov) - Jul 6, 2015
P2, N=80, Active, not recruiting, Sponsor: Kuopio University Hospital
N=60 --> 80 | Trial primary completion date: Dec 2014 --> Dec 2016 Recruiting --> Active, not recruiting
- || Zelboraf (vemurafenib) / Roche
Trial primary completion date: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers (clinicaltrials.gov) - Jul 2, 2015
P2, N=160, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2016 --> Apr 2017
- || bortezomib / Generic mfg., dexamethasone / Generic mfg.
Trial completion: Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT (clinicaltrials.gov) - Jul 2, 2015
P2/3, N=47, Completed, Sponsor: Tampere University Hospital
Trial primary completion date: Oct 2016 --> Apr 2017 Active, not recruiting --> Completed
- dinaciclib (MK-7965) / Merck (MSD)
Trial primary completion date, Combination therapy: Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Jul 1, 2015
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jun 2015 --> Jun 2016
- || fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Jun 30, 2015
P1/2, N=225, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Dec 2016 --> Mar 2015
- ||| Trial completion: Enzy-MagIC: The Effects of Enzymes and Flavonoids on Inflammation and Coagulation After Marathon (clinicaltrials.gov) - Jun 30, 2015
P1, N=160, Completed, Sponsor: Technische Universit
Trial primary completion date: Dec 2016 --> Mar 2015 Active, not recruiting --> Completed
- tabalumab (LY2127399) / Eli Lilly
Trial primary completion date, Combination therapy: A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib (clinicaltrials.gov) - Jun 29, 2015
P1, N=48, Completed, Sponsor: Applied Molecular Evolution
Active, not recruiting --> Completed Trial primary completion date: May 2014 --> Jan 2013
- decitabine / Generic mfg.
Enrollment change, Trial suspension: Decitabine for High-Risk Sickle Cell Disease (clinicaltrials.gov) - Jun 29, 2015
P2, N=10, Suspended, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: May 2014 --> Jan 2013 N=40 --> 10 | Recruiting --> Suspended
- | Mozobil (plerixafor) / Sanofi
Enrollment closed: Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma (clinicaltrials.gov) - Jun 26, 2015
P2, N=14, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
N=40 --> 10 | Recruiting --> Suspended Recruiting --> Active, not recruiting
- bortezomib / Generic mfg., lenalidomide / Generic mfg.
Trial termination, Trial primary completion date: Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone (clinicaltrials.gov) - Jun 26, 2015
P3, N=48, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated | Trial primary completion date: Apr 2013 --> Aug 2012; Slow accrual
- | Kovaltry (octocog alfa) / Bayer, CSL Behring
New P1 trial: Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate (clinicaltrials.gov) - Jun 26, 2015
P1, N=18, Not yet recruiting, Sponsor: Bayer
- dasatinib / Generic mfg.
Trial completion, Surgery, Metastases: S0711: Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 26, 2015
P1, N=80, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated | Trial primary completion date: Apr 2013 --> Aug 2012; Slow accrual Active, not recruiting --> Completed
- |||| Trial completion: A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure (clinicaltrials.gov) - Jun 25, 2015
P4, N=2395, Completed, Sponsor: Janssen Pharmaceutica N.V., Belgium
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Arzerra (ofatumumab) / Novartis, Genmab
Trial primary completion date: Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Jun 25, 2015
P2, N=3, Terminated, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: Jan 2014 --> Apr 2014
- Trial primary completion date: Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) - Jun 23, 2015
P=N/A, N=80, Recruiting, Sponsor: Michael A. Thompson, MD, PhD
Trial primary completion date: Jan 2014 --> Apr 2014 Trial primary completion date: Mar 2015 --> Dec 2015
- || cyclophosphamide / Generic mfg., pomalidomide / Generic mfg.
Combination therapy: Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide (clinicaltrials.gov) - Jun 23, 2015
P1/2, N=80, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Mar 2015 --> Dec 2015 Trial primary completion date: Dec 2015 --> Jun 2016
- || rocilinostat (ACY-1215) / Regenacy
Trial primary completion date, Combination therapy, Monotherapy: Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma (clinicaltrials.gov) - Jun 23, 2015
P1/2, N=120, Recruiting, Sponsor: Acetylon Pharmaceuticals Incorporated
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Sep 2015
- cyclophosphamide / Generic mfg., carfilzomib / Generic mfg.
Clinical: A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma (clinicaltrials.gov) - Jun 23, 2015
P1, N=38, Active, not recruiting, Sponsor: Academic Myeloma Consortium
Trial primary completion date: Dec 2015 --> Sep 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Aug 2015
- ||| New trial, HEOR: A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment (clinicaltrials.gov) - Jun 22, 2015
P=N/A, N=70, Recruiting, Sponsor: Hoffmann-La Roche
- Enrollment change, Trial termination, Trial primary completion date: Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy (clinicaltrials.gov) - Jun 22, 2015
P1, N=11, Terminated, Sponsor: University Health Network, Toronto
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Aug 2015 N=48 --> 11 | Recruiting --> Terminated | Trial primary completion date: Aug 2011 --> Sep 2013
- || Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial primary completion date, Patient reported outcomes: ECHO: Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (clinicaltrials.gov) - Jun 20, 2015
P=N/A, N=2000, Not yet recruiting, Sponsor: Bayer
N=48 --> 11 | Recruiting --> Terminated | Trial primary completion date: Aug 2011 --> Sep 2013 Trial primary completion date: Mar 2020 --> Jun 2020
- ||| New trial: Impact of Vasculitis on Employment and Income (clinicaltrials.gov) - Jun 20, 2015
P=N/A, N=400, Recruiting, Sponsor: University of South Florida
- Enrollment closed, Enrollment change, Trial primary completion date: Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 18, 2015
P1, N=24, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Mar 2020 --> Jun 2020 Recruiting --> Active, not recruiting | N=18 --> 24 | Trial primary completion date: Apr 2015 --> Apr 2016
- everolimus / Generic mfg.
Trial primary completion date: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Jun 17, 2015
P2, N=33, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | N=18 --> 24 | Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: Jul 2014 --> Jul 2016
- ||||| bortezomib / Generic mfg., prednisone / Generic mfg., melphalan / Generic mfg.
New P4 trial, Observational data: Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma (clinicaltrials.gov) - Jun 17, 2015
P4, N=171, Completed, Sponsor: Janssen Korea, Ltd., Korea
- Enrollment closed, Enrollment change, Trial primary completion date: Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers (clinicaltrials.gov) - Jun 17, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Jul 2014 --> Jul 2016 Recruiting --> Active, not recruiting | N=24 --> 30 | Trial primary completion date: Oct 2015 --> Apr 2015
- Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial initiation date: Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma (clinicaltrials.gov) - Jun 16, 2015
P2, N=50, Recruiting, Sponsor: University of Michigan Cancer Center
Recruiting --> Active, not recruiting | N=24 --> 30 | Trial primary completion date: Oct 2015 --> Apr 2015 Not yet recruiting --> Recruiting | Initiation date: Mar 2015 --> Jun 2015
- dexamethasone / Generic mfg., lenalidomide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P2 trial: Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients (clinicaltrials.gov) - Jun 15, 2015
P2, N=45, Recruiting, Sponsor: Meletios A. Dimopoulos
- | rVIIa-FP (CSL689) / CSL Behring
New P1 trial: Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency (clinicaltrials.gov) - Jun 12, 2015
P1, N=16, Not yet recruiting, Sponsor: CSL Behring